7 results about "Chronic urticaria" patented technology

The disclosure relates to pharmaceutical formulations and method of using chymase inhibitors for the prevention and treatment of mast cell-related disease states in which chymase is involved. More particularly the present disclosure is in the field of treating or preventing or reducing the symptoms of mast cell-related diseases, including atopic dermatitis (AD), chronic urticaria (CU), Eosinophilic Gastrointestinal Disorders (EGIDs), and prurigo nodularis (PN), using a chymase inhibitor, including a chymase inhibitor that prevents cleavage of stem cell factor (SCF) and its interaction with receptor tyrosine kinase (c-kit), thereby reducing mast cell activation and proliferation.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The present application relates to traditional Chinese medicine composition and its application in the field of skin inflammation diseases, and discloses a kind of drug composition for treating skin inflammation and its preparation method and application.The composition is prepared from white fungus, tribulus terrestris, smilax glabra, kochia scoparia, honeysuckle, baishiy, rehmannia glutinosa, oak, peony, radix lithospermi, periostracum cicadae, licorice, gardenia and sophora flavescens.The UPLC-Q-TOF-MS identification contains 110 kinds of components;Animal experiments show that it can significantly reduce psoriasis skin lesions, down-regulate TNF-alpha, IL-1beta and IL-6, up-regulate IL-10, and inhibit PI3K-Akt pathway.The present application has clear components, clear mechanism and definite curative effect, and can be used for preparing medicine for treating psoriasis, chronic urticaria and senile pruritus.

The present invention relates to a cosmetic composition comprising a combination of nerve growth factor (NGF) inhibitors, that is particularly of use in the topical treatment of pruritus, in particular, that observed in the case of psoriasis or of atopic dermatitis, of chronic urticaria and also of senile pruritus. The invention is directed towards a composition comprising an ambora extract and a green tea extract.

This invention relates to the field of traditional Chinese medicine, and more particularly to a traditional Chinese medicine composition, its preparation method, and its application. The invention provides a traditional Chinese medicine composition, by weight, comprising the following components or their processed forms: Ephedra 2-10 parts, Coptis chinensis 2-5 parts, Dictamnus dasycarpus root bark 5-10 parts, Cicadae periostracum 3-6 parts, Spirodela polyrhiza 3-9 parts, Schizonepeta tenuifolia 5-10 parts, Astragalus membranaceus 9-20 parts, Eriobotrya japonica leaf 5-10 parts, Salvia miltiorrhiza 5-15 parts, Atractylodes macrocephala 5-12 parts, Sophora flavescens 4-9 parts, and Glycyrrhiza uralensis 3-10 parts. This invention has unique advantages in treating chronic urticaria, reducing the frequency of urticaria attacks, improving antipruritic effects, reducing recurrence, and prolonging the recurrence period.

This invention relates to the field of pharmaceutical technology, disclosing the application of *Melastoma candida* polysaccharide in the preparation of drugs for the prevention or treatment of chronic urticaria. This invention is the first to discover that *Melastoma candida* polysaccharide can regulate immune homeostasis, inhibit inflammatory responses, improve skin lesions, and restore intestinal flora balance through multiple pathways. It also inhibits the overactivation of the NGF / TRPV1 / p38 signaling pathway, reduces neurogenic inflammation and mast cell-mediated responses, thereby alleviating the pathological process of chronic urticaria. This broadens the application scope of *Melastoma candida* polysaccharide and provides a new approach for the treatment of allergic skin-related diseases.

Provided herein are methods of treating conditions associated with activation or over-activation of mast cells is acute or chronic urticaria, mastocytosis or any subtype of mastocytosis, pseudo-allergy, any form of dermatitis, such as contact or atopic dermatitis, wound healing, rosacea, acne, or psoriasis, food allergy, or irritable bowel syndrome. The method comprises administering a MRGPRD agonist, such as beta alanine, GABA, β-AIBA, or 5-oxoETE to a patient to treat the condition. Topical, enteric, delayed-release, or aerosol dosage forms comprising beta-alanine also are provided.